Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
Patient Perspectives: Clinical Trials Experiences Through Storytelling
dbrock
Patient Perspectives: Clinical Trials Experiences Through Storytelling - An Invitation to Apply
Image
We are very excited to launch a new program for GRACE
Patient Perspectives: Clinical Trials Experiences Through Storytelling
**Please Note -- We have extended the deadline for applications to Friday, March 19, 2021. Don't delay!! fill out the application today!
We are inviting all cancer patients with experience in clinical trials (no matter how large or small) to join us in this new program giving voice to the clinical trials experience.
Through storytelling and sharing their experience, patients can educate others who are considering a clinical trial about this part of the cancer journey. All cancer patients currently enrolled in or with past enrollment in a clinical trial are welcomed and encouraged to apply.
Patients selected to participate in this year's program will work closely with GRACE to develop new educational content for patients across a range of platforms that will help them to become established contributors in the area of advocacy. Participants will receive training on digitally distributed content and social media, and their work will be highlighted and shared by GRACE, along with its network of established leaders in the oncology community and board members with an array of interests and connections. Participants will receive a stipend, training in communication and media platforms, and a tech 'package'. Participants will work with GRACE to develop program formats and production and will present a proposal based on their area of experience in a clinical trial program.
For more information, please take a look at and complete our online Program Form and Application, or download the .pdf version available above, which can be emailed as an attachment to dbrock@cancerGRACE.org. If you have questions please contact Denise Brock, Operations Director for GRACE at dbrock@cancerGRACE.org.
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Video
In this series, the 2024-25 Clinical Trials Experiences Through Storytelling Program, we talk to cancer survivors who have a passion for telling their stories in order to help others who may be navigating the clinical trials experience.
In this 2nd series of videos, Michael Herman takes us through the story of his diagnosis, his struggles with treatment options, his clinical trial and his learning curve.
Thank you to our Sponsors! #lilly #exelixis
Article
Head and neck cancers linked to human papillomavirus (HPV) are very different from those caused by tobacco or alcohol. The good news is that HPV-positive cancers usually respond better to treatment and often have better outcomes.
Image
Video
In this series, the 2024-25 Clinical Trials Experiences Through Storytelling Program, we talk to cancer survivors who have a passion for telling their stories in order to help others who may be navigating the clinical trials experience.
Online Community
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
- The antibody, which serves as the “horse,” specifically targets a protein found on cancer...
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.